600771.SHG GuangYuYuan Chinese Herbal Medicine Co Ltd
- Market cap
- CNY 6.36B
- P/E
- 130.0x
- P/B
- 3.77x
- ROE
- 6.3%
- Dividend yield
- 0.02%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600771.SHG undervalued?
Graham numberThe Graham number of GuangYuYuan Chinese Herbal Medicine Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GuangYuYuan Chinese Herbal Medicine Co Ltd fundamental analysis
No fundamental analysis for GuangYuYuan Chinese Herbal Medicine Co Ltd yet.
GuangYuYuan Chinese Herbal Medicine Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GuangYuYuan Chinese Herbal Medicine Co Ltd
GuangYuYuan Chinese Herbal Medicine Co., Ltd. manufactures and sells Chinese medicinal products. The company offers traditional Chinese medicine, fine Chinese medicine, and health wine. It provides its products in the form of pills, powders, tablets, hard capsules, granules, compound preparations, and medicated eight dosage forms. The company was formerly known as Topsun Science And Technology Co Ltd. and changed its name to GuangYuYuan Chinese Herbal Medicine Co., Ltd. in J…
Full company profileGuangYuYuan Chinese Herbal Medicine Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GuangYuYuan Chinese Herbal Medicine Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 937M | 1.17B | 1.62B | 1.22B | 1.11B | 854M | 1.13B | 1.28B | 1.22B | 1.37B | 1.34B |
| Gross Profit | 730M | 962M | 1.31B | 946M | 783M | 521M | 726M | 933M | 891M | 926M | 887M |
| Operating Income | 180M | 280M | 458M | 140M | -299K | -371M | -273M | 115M | 90.8M | 139M | 135M |
| EBITDA | 186M | 285M | 484M | 207M | 47.9M | -324M | -188M | 152M | 133M | 154M | 122M |
| Net Income | 123M | 237M | 374M | 130M | 32.0M | -316M | -250M | 90.1M | 74.5M | 63.0M | 105M |
| EPS | 0.31 | 0.48 | 1.06 | 0.27 | 0.07 | -0.65 | -0.51 | 0.18 | 0.15 | 0.13 | 0.22 |
| Balance Sheet | |||||||||||
| Total Assets | 2.14B | 2.52B | 3.08B | 3.54B | 3.80B | 3.10B | 2.72B | 2.63B | 2.28B | 2.44B | 2.40B |
| Total Liabilities | 414M | 537M | 723M | 1.10B | 1.33B | 962M | 996M | 1.12B | 685M | 784M | 716M |
| Shareholders' Equity | 1.71B | 1.91B | 2.29B | 2.36B | 2.41B | 2.10B | 1.70B | 1.50B | 1.57B | 1.63B | 1.66B |
| Cash & Short-term Investments | 968M | 281M | 125M | 238M | 394M | 145M | 246M | 259M | 117M | 297M | 327M |
| Total Debt | 41.3M | 110M | 192M | 173M | 336M | 328M | 433M | 291M | 53.7M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -212M | -184M | -298M | -141M | -75.5M | 81.4M | 253M | 215M | 112M | 198M | - |
| Capital Expenditure | 174M | 285M | 200M | 87.4M | 49.6M | 18.2M | 8.67M | 2.51M | 8.78M | 6.24M | 6.89M |
| Free Cash Flow | -386M | -469M | -498M | -228M | -125M | 63.2M | 245M | 213M | 104M | 192M | 295M |
| Ratios | |||||||||||
| ROE | 7.2% | 12.4% | 16.4% | 5.5% | 1.3% | -15.1% | -14.7% | 6.0% | 4.7% | 3.9% | 6.3% |
| ROA | 5.7% | 9.4% | 12.2% | 3.7% | 0.8% | -10.2% | -9.2% | 3.4% | 3.3% | 2.6% | 4.4% |
| Net Profit Margin | 13.1% | 20.3% | 23.1% | 10.7% | 2.9% | -37.0% | -22.1% | 7.0% | 6.1% | 4.6% | 7.9% |
| Debt to Equity | 0.02x | 0.06x | 0.08x | 0.07x | 0.14x | 0.16x | 0.25x | 0.19x | 0.03x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
GuangYuYuan Chinese Herbal Medicine Co Ltd dividends
- Dividend yield
- 0.02%
- Forward dividend
- -
- Payout ratio
- 1.9%
- Ex-dividend date
- Jul 30, 2003
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.19M | 0.00 | 1.9% |
| 2024 | CNY 3.95M | 0.01 | 5.3% |
| 2023 | CNY 14.3M | 0.03 | 15.9% |
| 2022 | CNY 19.8M | 0.04 | - |
| 2021 | CNY 18.3M | 0.04 | - |
| 2020 | CNY 11.0M | 0.02 | 34.5% |
| 2019 | CNY 12.7M | 0.03 | 9.8% |
| 2018 | CNY 27.2M | 0.08 | 7.3% |
| 2017 | CNY 1.64M | 0.00 | 0.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on May 30, 2019.
Who owns GuangYuYuan Chinese Herbal Medicine Co Ltd
- Insiders 21.12%
- Institutions 1.73%
- Public & others 77.15%
- Shares outstanding 489M
- Free float 386M
GuangYuYuan Chinese Herbal Medicine Co Ltd company profile
- Company name
- GuangYuYuan Chinese Herbal Medicine Co Ltd
- Ticker
- 600771.SHG
- ISIN
- CNE000000MY1
- Exchange
- Shanghai Stock Exchange
- Listed since
- Oct 16, 1996
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,744
- Fiscal year end
- December
- Address
- Shanxi Wutong Building, Taiyuan, China, 030000
- Phone
- 86 35 1709 9061
- Website
- guangyuyuan.com
About GuangYuYuan Chinese Herbal Medicine Co Ltd
GuangYuYuan Chinese Herbal Medicine Co., Ltd. manufactures and sells Chinese medicinal products. The company offers traditional Chinese medicine, fine Chinese medicine, and health wine. It provides its products in the form of pills, powders, tablets, hard capsules, granules, compound preparations, and medicated eight dosage forms. The company was formerly known as Topsun Science And Technology Co Ltd. and changed its name to GuangYuYuan Chinese Herbal Medicine Co., Ltd. in July 2013. GuangYuYuan Chinese Herbal Medicine Co., Ltd. was founded in 1996 and is headquartered in Taiyuan, China.
GuangYuYuan Chinese Herbal Medicine Co Ltd management
7- Mr. Yan RenExecutive VP, CFO & Director · born 1988
- Ms. Yun TangVP & Board Secretary · born 1972
- Mr. Huazhong ZhangVice President · born 1980
- Ms. Orchid WillowVice President · born 1974
- Mr. Hong Yu LuVice President · born 1980
- Li QiaoDeputy Director of the Board Office & Securities Affairs Representative
- Mr. Penghao WangVice President · born 1975